Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Cost of Revenue (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Cost of Revenue for 16 consecutive years, with $11.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 15.14% to $11.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $49.0 million, a 11.62% increase, with the full-year FY2025 number at $49.0 million, up 11.62% from a year prior.
  • Cost of Revenue was $11.4 million for Q4 2025 at Anika Therapeutics, down from $12.2 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $17.7 million in Q4 2021 to a low of -$8.7 million in Q4 2023.
  • A 5-year average of $11.8 million and a median of $13.7 million in 2024 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: crashed 137.1% in 2022, then surged 255.4% in 2024.
  • Anika Therapeutics' Cost of Revenue stood at $17.7 million in 2021, then plummeted by 137.1% to -$6.6 million in 2022, then crashed by 32.15% to -$8.7 million in 2023, then soared by 255.4% to $13.5 million in 2024, then fell by 15.14% to $11.4 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Cost of Revenue are $11.4 million (Q4 2025), $12.2 million (Q3 2025), and $13.9 million (Q2 2025).